Evaluation of SCOUT DS in Subjects With Type 2 Diabetes #2
TCOYD2
An Evaluation of a Noninvasive Diabetes Screening Device in Subjects at the TCOYD Diabetes Conference
1 other identifier
observational
264
1 country
1
Brief Summary
The primary objective of the trial is to collect SCOUT DS and Hemoglobin A1c measurements of subjects who have been diagnosed with Type 2 diabetes.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started May 2011
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 28, 2011
CompletedStudy Start
First participant enrolled
May 1, 2011
CompletedFirst Posted
Study publicly available on registry
May 2, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2011
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2011
CompletedDecember 5, 2012
December 1, 2012
3 months
April 28, 2011
December 3, 2012
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Continuing validation of SCOUT DS algorithm
Collect SCOUT DS and Hemoglobin A1c measurements of subjects with Type 2 Diabetes
1 day
Study Arms (2)
Those with Type 2 diabetes
270 subjects with Type 2 diabetes
Non diabetic
30 healthy subjects
Eligibility Criteria
Attendees of the Taking Control of Your Diabetes Health Fair, Albuquerque Convention Center
You may qualify if:
- Age greater than or equal to 18 years Self-reported diagnosis of type 2 diabetes No Self-reported diagnosis of type 2 diabetes
You may not qualify if:
- Less than 18 years of age
- Diagnosed with type 1 diabetes
- Known to be pregnant (Self Reported)
- Receiving dialysis or having known renal compromise
- Scars, tattoos, rashes or other disruption/discoloration on the left volar forearm.
- Known to have, or at risk for, photosensitivity reactions ( e.g., sensitive to ultraviolet light, or taking medication known to cause photosensitivity)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- VeraLight, Inc.lead
Study Sites (1)
Albuquerque Convention Center
Albuquerque, New Mexico, 87102, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Walter Forman, MD
Lovelace Scientific Resources
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 28, 2011
First Posted
May 2, 2011
Study Start
May 1, 2011
Primary Completion
August 1, 2011
Study Completion
August 1, 2011
Last Updated
December 5, 2012
Record last verified: 2012-12